Pancreatic stents in ERCP. Where are we?

Rev Esp Enferm Dig. 2018 Jul;110(7):413-415. doi: 10.17235/reed.2018.5670/2018.

Abstract

Post-ERCP pancreatitis (PEP) is a common complication most feared by endoscopists. Incidence ranges widelly from 2.1% to 24.4%, which results from patient heterogeneity and differences in endoscopist expertise, method, PEP definition, and severity. Pathophysiology is multifactorial, and involves a combination of chemical, thermal, mechanical, hydrostatic, enzymatic, allergic, and microbiological factors resulting from papillary instrumentation and/or contrast administration within the pancreatic duct (volume and osmolarity). Even genetic abnormalities may represent a risk factor, as is the case with homozygous alpha-1-antitrypsin deficiency, which leads to an increase in hemorrhagic PEP rates.

Publication types

  • Comment

MeSH terms

  • Catheterization
  • Cholangiopancreatography, Endoscopic Retrograde
  • Humans
  • Pancreatic Ducts*
  • Pancreatitis*
  • Risk Factors
  • Stents